Cyveen Weerarantha | Digital Health and Computational Biology | Research Excellence Award

Research Excellence Award

Cyveen Weeraratna
Affiliation Royal Melbourne Hospital
Country Australia
Scopus ID 56151709400
Documents 4
Citations 70
h-index 3
Subject Area Digital Health and Computational Biology
Event Computational Biologists Awards
ORCID 0009-0000-6689-4623

Cyveen Weeraratna
Royal Melbourne Hospital

Cyveen Weerarantha is affiliated with the Royal Melbourne Hospital, Australia, and has contributed to research spanning digital health and computational biology. The Research Excellence Award recognizes scholarly achievements that demonstrate scientific quality, interdisciplinary collaboration, and measurable research influence. Within this context, the researcher represents an emerging contributor whose published work, citation record, and involvement in computational health research align with the objectives of academic recognition and professional excellence.[1]

Abstract

The Research Excellence Award recognizes investigators whose scholarly activities demonstrate sustained scientific quality, meaningful research impact, and contributions to advancing knowledge within their discipline. Cyveen Weerarantha’s academic profile reflects involvement in digital health and computational biology through publications that support data-driven healthcare research and interdisciplinary collaboration. Bibliometric indicators, including publications, citations, and an established h-index, provide measurable evidence of scholarly engagement. These achievements, combined with institutional affiliation and participation in computational health research, illustrate an emerging academic profile consistent with the principles of excellence, innovation, research integrity, and professional contribution.[1][2]

Keywords

Digital Health, Computational Biology, Biomedical Informatics, Clinical Research, Health Data Analytics, Research Excellence, Scientific Impact, Translational Medicine.

Introduction

Digital health and computational biology continue to reshape biomedical research by integrating advanced computational techniques with clinical practice and biological sciences. Researchers working within these domains contribute to improved diagnostic methodologies, health data interpretation, and evidence-based decision making. Recognition through research awards reflects scientific productivity together with ethical scholarship, interdisciplinary collaboration, and measurable academic influence within evolving healthcare environments.[2]

Research Profile

Cyveen Weerarantha is associated with the Royal Melbourne Hospital in Australia and maintains an indexed publication record within Scopus. Research activities emphasize computational approaches supporting healthcare research, reflecting collaboration across clinical and data science disciplines. Bibliometric indicators demonstrate developing academic influence supported by published literature and citation performance that contributes to ongoing scientific communication and knowledge dissemination.[1]

Research Contributions

The research contributions associated with this profile emphasize computational analysis applied to healthcare challenges, integrating biological information with digital technologies to improve research methodologies. Such work supports evidence generation, promotes interdisciplinary collaboration, and contributes to broader understanding of data-driven healthcare solutions. These efforts reflect the growing importance of computational biology in modern clinical research and biomedical innovation.[3]

Publications

The researcher has four indexed publications that collectively contribute to the scientific literature within digital health and computational biology. Citation activity demonstrates continuing academic visibility, while publication in peer-reviewed venues supports knowledge exchange and encourages future collaborative investigations. Published studies provide a measurable foundation for evaluating research productivity and scholarly engagement within the discipline.[1]

Research Impact

Research impact is commonly evaluated through publication quality, citation performance, scholarly visibility, and contribution to advancing scientific understanding. The available bibliometric indicators demonstrate meaningful engagement with the academic community, while interdisciplinary research strengthens the relevance of computational approaches within healthcare. Such measurable outcomes support recognition through professional and institutional award programs.[4]

Award Suitability

The Research Excellence Award acknowledges researchers demonstrating scientific rigor, measurable scholarly achievement, and continuing contributions to their academic field. Cyveen Weerarantha’s publication record, citation metrics, institutional affiliation, and research focus within computational biology and digital health collectively align with the evaluation principles commonly applied to emerging research excellence awards, emphasizing quality, collaboration, and sustained scholarly development.[1][4]

Conclusion

Cyveen Weerarantha’s scholarly profile illustrates an emerging contribution to computational biology and digital health supported by indexed publications, citations, and interdisciplinary collaboration. These characteristics reflect academic engagement that is consistent with the objectives of the Research Excellence Award, recognizing research quality, scientific integrity, and the advancement of evidence-based healthcare through computational innovation.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Cyveen Weerarantha, Author ID 56151709400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56151709400
  2. American Journal of Kidney Diseases. (2018). Attempts to Change the Globally Accepted Term, CKDu, to KDUCAL, NUCAL, or CINAC Are Inappropriate..
    https://doi.org/10.1053/j.ajkd.2018.01.033
  3. Critical Care and Resuscitation. (2026). Sustainable continuous renal replacement therapy: The influence of blood flow rates, effluent dose, autoeffluent, and citrate anticoagulation on carbon dioxide emissions.
    https://doi.org/10.1016/j.ccrj.2026.100176
  4. Computational Biologists Awards. Research Excellence Award.
    https://computationalbiologists.com/

Hua Zhu | AI in Drug Discovery | Best Researcher Award

Prof. Hua Zhu | AI in Drug Discovery | Best Researcher Award   

Researcher, Ph.D. Supervisor at  Beijing Cancer Hospital & Institute, Peking University, China.
Prof. Hua Zhu is a distinguished researcher and full professor at the Department of Nuclear Medicine, Beijing Cancer Hospital & Institute, Peking University. With a focused career in molecular imaging and nuclear medicine, Prof. Zhu has made pioneering contributions to the clinical translation of cancer theranostics. His extensive work in radiopharmaceuticals, multimodality molecular probes, and targeted delivery systems places him among the leading scientists in his field.

🎓 Academic Background:

Prof. Zhu earned his Bachelor of Science degree in Applied Chemistry from Nanjing Normal University in 2006, followed by a Ph.D. in Inorganic Chemistry (specializing in Radiopharmaceuticals) from the Shanghai Institute of Applied Physics, Chinese Academy of Sciences in 2011. He also enriched his academic perspective through a visiting assistant professorship at Stanford University from 2014 to 2015.

Profile:

Professional Experience:

Prof. Hua Zhu is a full professor at the Department of Nuclear Medicine, Beijing Cancer Hospital & Institute, Peking University. He has over a decade of professional experience in the development of molecular imaging agents and targeted radiopharmaceuticals for cancer diagnosis and therapy. He has led multiple national-level research projects and previously served as a visiting assistant professor at Stanford University, contributing to international research collaboration. His expertise spans from radionuclide production to clinical translation, and he actively holds leadership roles in key academic societies related to nuclear medicine and imaging science.

🧪 Research Focus:

Prof. Zhu’s research is dedicated to the development of molecular imaging tools and targeted delivery systems for cancer diagnosis and treatment. His focus areas include the production and application of solid-target based radionuclides such as ⁶⁴Cu, ⁸⁹Zr, and ¹²⁴I, and the design of multimodal imaging probes. His efforts are instrumental in bridging the gap between bench research and clinical oncology.

🏆 Academic Honors:

Prof. Zhu has received numerous prestigious honors that recognize his research excellence and leadership in the field:

  • 🌟 National-level Young Talent (2023)

  • 🧠 Young Beijing Scholar (2024)

  • 📘 Boya Young Scholar (2025)

  • 🌆 “Bai Qian Wan” Talent of Beijing (2019)

  • 💫 Beijing Young Top-notch Talent (2018)

  • Beijing Nova Program (2017)

🔬 Research Leadership:

As a principal investigator, Prof. Zhu leads four National Natural Science Foundation of China (NSFC) projects and over ten national/provincial initiatives. His work exemplifies effective leadership in interdisciplinary and cross-institutional collaboration.

Publications:

  1. Detectability of Al¹⁸F-NOTA-HER2-BCH PET for Nodal Metastases in Patients With HER2-Positive Breast Cancer
    Clinical Nuclear Medicine, 2025

  2. Construction of Bispecific T-Cell Engager Radiotracer and Its Micro-PET Evaluation in Pancreatic Cancer
    Molecular Pharmaceutics, 2025

  3. Radiolabelled Anti-PD-L1 Peptide PET/CT in Predicting the Efficacy of Neoadjuvant Immunotherapy Combined With Chemotherapy in Resectable Non-Small Cell Lung Cancer
    Annals of Nuclear Medicine, 2025

  4. [¹⁷⁷Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma
    Bioconjugate Chemistry, 2025

  5. A Whole-Body Imaging Technique for Tumor-Specific Diagnostics and Screening of B7H3-Targeted Therapies
    Journal of Clinical Investigation, 2025 (Open Access)

  6. Development and First-in-Human Evaluation of a Site-Specific [¹⁸F]-Labeled PD-L1 Nanobody PET Radiotracer for Noninvasive Imaging in NSCLC
    Bioorganic Chemistry, 2025

  7. Radioiodinated Nanobody ImmunoPET Probe for In Vivo Detection of CD147 in Pan-Cancer
    European Journal of Nuclear Medicine and Molecular Imaging, 2025

  8. Strategies for Specific Multimodal Imaging of Cancer-Associated Fibroblasts and Applications in Theranostics of Cancer
    Open Access Review

  9. Efficacy of Radiolabelled PD-L1-Targeted Nanobody in Predicting and Evaluating the Combined Immunotherapy and Chemotherapy for Resectable Non-Small Cell Lung Cancer
    European Journal of Nuclear Medicine and Molecular Imaging, 2025

  10. Recent Advances in Emerging Radiopharmaceuticals and the Challenges in Radiochemistry and Analytical Chemistry
    Review Article, 2025